1 Min Read
April 27 (Reuters) - Ultragenyx Pharmaceutical Inc:
* Ultragenyx initiates global phase 3 study of UX007 in GLUT1 DS patients with disabling movement disorders Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.